#### **Supporting Information**

### Camphor Sulfonyl Hydrazines (CaSH) as Organocatalysts in Enantioselective Diels-Alder Reactions

Hao He, Bao-Jian Pei, Ho-Hsuan Chou, Tian Tian, W. H. Chan, and Albert W. M. Lee

Department of Chemistry, Hong Kong Baptist University, Kowloon Tong, Hong Kong SAR, China

#### Contents

General Methods and Materials	<b>S</b> 1
Experimental Procedures and Characterizations	S2
Refernce	S17
Selected HPLC chromatograms of compounds of Tables 4	S18
Selected NMR spectra of Table 3 and Table 4	S21

**General Methods.** Unless otherwise noted, solvents and starting materials were obtained from commercial suppliers. All chemicals used were of reagent grade without further purification before use. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Varian INOVA Unity (400 MHz for <sup>1</sup>H, and 100 MHz for <sup>13</sup>C) in CDCl<sub>3</sub>. Chemical shifts were recorded in ppm ( $\delta$ ) relative to CHCl<sub>3</sub> on 7.26 for <sup>1</sup>H NMR, 77.0 for <sup>13</sup>C NMR. Optical rotations were taken on a JASCO DIP-1000 digital polarimeter. FT-IR was recorded on a PerkinElmer Spectrum 100 FT/IR spectrometer. High resolution mass spectra (HRMS) were recorded on a QSTAR Pulsar/LC/MS/MS System, ESI-QTOF instrument (Applied Biosystem) or Bruker Autoflex MALDI-TOF MS instrument. HPLC analysis was performed on a Hewlett Packard Series 1050 HPLC, UV detection monitored at 230 nm, using Chiralcel OD (0.46 cm × 25 cm), Chiracel OD Guard (0.46 × 5 cm), Chiralcel OD-H (0.46 cm × 15 cm), and Chiralpak AD-H (0.46 cm × 25 cm).

#### **Experimental Procedures and Characterizations.**



(1S)-(+)-10-Camphorsulfonyl chloride 1 (2.5 g, 10 mmol) in 20 ml of methanol was added hydrazine monohydrate (0.97 ml, 20 mmol) and 2 acetic acid (0.29 ml, 5 mmol). The mixture was stirred at 80 °C to reflux for 4 hours. The reaction was cooled down. After remove the organic solvent by evaporator, the resulting mixture was dissolved in small amount of water and extracted with ethyl acetate for three times. The aqueous phase was basified by NaOH pellets to PH=9-10 and extracted with ethyl acetate for another three times. The combined six times extracting organic layer was washed with brine and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>, followed by filtration and concentration to obtain 2.1 g white solid of cyclic camphor sulfonyl hydrazone **2** in 92% yield. Mp 183-185 °C;  $[\alpha]^{20}_{D}$ = -13.1 (c = 1.03, CHCl<sub>3</sub>); IR (neat) 3253, 2974, 1319, 1164 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.73 (s, 1H), 3.24-3.12 (m, 2H), 2.58-2.52 (m, 1H), 2.40-2.33 (m, 1H), 2.06-2.01 (m, 2H), 1.98-1.91 (m, 1H), 1.81-1.74 (m, 1H), 1.42-1.36 (m, 1H), 0.98 (s, 3H), 0.90 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 165.1, 55.9, 49.2, 48.0, 44.2, 36.0, 31.0, 26.9, 19.8, 17.9; HRMS (ESI) C<sub>10</sub>H<sub>17</sub>N<sub>2</sub>O<sub>2</sub>S (M+H)<sup>+</sup> calcd. 229.1010, found 229.1000.


(S)-(-)-Cyclic camphor sulfonyl hydrazone (2)

To a solution

(S)-(-)-Cyclic camphor sulfonyl hydrazine (4) To a solution of cyclic camphor sulfonyl hydrazone 2 (228 mg, 1 mmol) in 3 ml of methanol was added 1.5 ml of acetic acid, followed by adding

NaCNBH<sub>3</sub> dropwise. The reaction was stirred at room temperature for 8 hours by the consumption of starting material. The excess NaCNBH<sub>3</sub> was quenched by 4N aqueous HCl solution. After remove the organic solvent by evaporator, the resulting mixture was basified by NaOH pellets to PH=9-10 and extracted with ethyl acetate for three times. The combined organic layer was washed with brine and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>, followed by further purification via column chromatography to give 225 mg white solid of cyclic camphor sulforyl hydrazine 4 in 98% yield.


Mp 179-181 °C;  $[\alpha]^{20}_{D}$  = -89.0 (c = 1.04, CHCl<sub>3</sub>); IR (neat) 3159, 2962, 1352, 1165 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  5.63 (s, 1H), 4.10 (br, 1H), 3.36 (d, *J* = 14.8 Hz, 1H), 3.12 (d, *J* = 14.8 Hz, 1H), 3.08 (dd, *J* = 8.8, 4.8 Hz, 1H), 1.83-1.80 (m, 1H), 1.77-1.70 (m, 2H), 1.64-1.57 (m, 2H), 1.34 (s, 3H), 1.27-1.21 (m, 1H), 1.18-1.11 (m, 1H), 0.95 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  63.0, 50.0, 49.6, 46.7, 45.6, 37.6, 34.0, 26.0, 21.1, 20.4; HRMS (MALDI-TOF) C<sub>10</sub>H<sub>19</sub>N<sub>2</sub>O<sub>2</sub>S (M+H)<sup>+</sup> calcd. 231.1162, found 231.1176.



(S)-(-)- $N^{\beta}$ -benzyl cyclic camphor sulfonyl hydrazine (6) To a solution of cyclic camphor sulfonyl hydrazine 4 (230 mg, 1 mmol) in 5 ml of dichloromethane was added potassium carbonate (138


6 mg, 1 mmol), tetrabutylammonium bromide (32 mg, 0.1 mmol), and followed by benzyl bromide (0.12 ml, 1 mmol). The reaction was stirred at room temperature for 2 days. Water was added and the resulting mixture was extracted by ethyl acetate for three times. The combined organic layer was washed with brine and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>, followed by further purification via column chromatography to give 212 mg white solid of **6** in 66% yield. Mp 187-189 °C;  $[\alpha]^{20}_{D} = -150.6$  (c = 1.005, CHCl<sub>3</sub>); IR (neat) 3156, 2950, 1332, 1156 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.36-7.26 (m, 5H), 4.74 (s, 1H), 4.09 (d, *J* = 14.8 Hz, 1H), 3.69 (d, *J* = 14.8 Hz, 1H), 3.29 (d, *J* = 14.8 Hz, 1H), 2.91 (d, *J* = 15.2 Hz, 1H), 2.53 (dd, *J* = 8.2, 5.0 Hz, 1H), 1.99-1.94 (m, 1H), 1.85-1.83 (m, 1H), 1.78-1.66 (m, 2H), 1.63-1.56 (m, 1H), 1.41 (s, 3H), 1.27-1.12 (m, 2H), 0.94 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 134.3, 129.3, 128.4, 127.5, 68.4, 57.2, 50.2, 49.9, 47.1, 46.0, 37.5, 35.1, 26.6, 20.7, 20.4; HRMS (MALDI-TOF) C<sub>17</sub>H<sub>25</sub>N<sub>2</sub>O<sub>2</sub>S (M+H)<sup>+</sup> calcd. 321.1631, found 321.1621.

General procedure for preparation of  $N^{\alpha}$ -acylated cyclic camphor sulfonyl hydrazines (7a-c) To a solution of cyclic camphor sulfonyl hydrazine 4 (1 mmol) in 4 ml of dichloromethane was added 4-(Dimethylamino)pyridine (1.1 mmol). Acid anhydride or acid chloride (1.1 mmol) was then dropped into the stirring reaction mixture at room temperature. After consumption of the starting material (tracked by TLC), the reaction mixture was put into ethyl acetate and washed with water and brine, dried with anhydrous  $Na_2SO_4$ , followed by further purification via column chromatography to give a white solid of **7a-c** in 95-99% yield.




(S)-(-)- $N^{\alpha}$ -acetyl cyclic camphor sulfonyl hydrazines (7a) Prepared according to the general procedure with acetic anhydride to provide the title compound as a white solid in 95% yield; Mp 159-160 °C;  $[\alpha]^{20}_{D} = -33.0$  (c = 1.015, CHCl<sub>3</sub>); IR (neat) 3287, 2955, 1683,

1347, 1252, 1166 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  5.41 (d, J = 5.2 Hz, 1H), 3.46 (d, J = 14.8 Hz, 1H), 3.24 (d, J = 14.8 Hz, 1H), 3.07-3.03 (m, 1H), 2.44 (s, 3H), 1.85-1.72 (m, 4H), 1.66-1.60 (m, 1H), 1.39 (s, 3H), 1.24-1.14 (m, 2H), 0.96 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  168.5, 63.2, 53.4, 50.9, 46.9, 45.3, 35.8, 33.8, 26.1, 23.7, 20.6, 20.3; HRMS (MALDI-TOF) C<sub>12</sub>H<sub>20</sub>N<sub>2</sub>NaO<sub>3</sub>S (M+Na)<sup>+</sup> calcd. 295.1087, found 295.1082.



(*S*)-(-)- $N^{\alpha}$ -<sup>*t*</sup>BOC cyclic camphor sulfonyl hydrazines (7b) Prepared according to the general procedure with di-*tert*-butyl dicarbonate to provide the title compound as a white solid in 99% yield; Mp 111-113 °C;  $[\alpha]^{20}_{D} = -51.5$  (c = 1.015, CHCl<sub>3</sub>); IR (neat) 3347, 2947, 1737, 1360, 1298, 1177, 1139 cm<sup>-1</sup>; <sup>1</sup>H NMR


(400 MHz, CDCl<sub>3</sub>)  $\delta$  4.70 (d, J = 8.4 Hz, 1H), 3.40 (d, J = 14.8 Hz, 1H), 3.28 (d, J = 14.8 Hz, 1H), 3.21-3.15 (m, 1H), 1.82-1.68 (m, 4H), 1.65-1.58 (m, 1H), 1.53 (s, 9H), 1.33 (s, 3H), 1.28-1.22 (m, 1H), 1.18-1.12 (m, 1H), 0.94 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  150.7, 84.8, 62.9, 52.6, 51.0, 46.9, 45.2, 36.0, 34.0, 27.9, 26.0, 20.8, 20.4; HRMS (ESI) C<sub>15</sub>H<sub>27</sub>N<sub>2</sub>O<sub>4</sub>S (M+H)<sup>+</sup> calcd. 331.1691, found 331.1685.



(*S*)-(-)- $N^{\alpha}$ -benzoyl cyclic camphor sulfonyl hydrazines (7c) Prepared according to the general procedure with benzoyl chloride to provide the title compound as a white solid in 99% yield; Mp 131-133 °C;  $[\alpha]^{20}_{D} = -67.6$  (c = 1.1, CHCl<sub>3</sub>); IR (neat) 3330, 2964, 1677, 1362, 1171 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)

δ 7.72-7.70 (m, 2H), 7.56-7.52 (m, 1H), 7.45-7.40 (m, 2H), 5.09 (d, *J* = 8.0 Hz, 1H), 3.47 (d, *J* = 14.8 Hz, 1H), 3.35 (d, *J* = 14.4 Hz, 1H), 3.35 (dd, *J* = 21.6, 5.2 Hz, 1H), 1.85-1.59 (m, 5H), 1.31 (s, 3H), 1.30-1.24 (m, 1H), 1.19-1.13 (m, 1H), 0.97 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 169.9, 133.4, 132.3, 129.2, 127.7, 62.5, 52.6, 50.6, 46.8, 45.3, 36.4, 34.0, 25.8, 21.0, 20.3; HRMS (MALDI-TOF) C<sub>17</sub>H<sub>23</sub>N<sub>2</sub>O<sub>3</sub>S (M+H)<sup>+</sup> calcd. 335.1424, found 335.1413.

General procedure for preparation of  $N^{a}$ -alkylated cyclic camphor sulfonyl hydrazones (3a-f) To a solution of cyclic camphor sulfonyl hydrazone 2 (5 mmol) in 20 ml THF was added sodium hydroxide (10 mmol) and tetrabutylammonium bromide (2 mmol), followed by alkyl halide (10 mmol). The reaction mixture was stirred at room temperature. After consumption of the starting material (tracked by TLC), water was added and THF was removed by evaporation. The resulting mixture was extracted by ethyl acetate for three times and the combined organic layer was washed with brine and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>, followed by further purification via column chromatography to give compound **3a-f** in 82-97% yield.




(*S*)-(-)- $N^{\alpha}$ -benzyl cyclic camphor sulfonyl hydrazone (3a) Prepared according to the general procedure with benzyl bromide to provide the title compound as a white solid in 97% yield; Mp 100-101 °C;  $[\alpha]^{20}_{D} = -77.2$  (c = 1.02, CHCl<sub>3</sub>); IR (neat) 2971, 1323, 1145 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.33-7.20

(m, 5H), 4.78 (d, J = 14.8 Hz, 1H), 4.49 (d, J = 15.2 Hz, 1H) 3.10 (d, J = 13.6 Hz, 1H), 2.99 (d, J = 13.2 Hz, 1H), 2.47-2.41 (m, 1H), 2.36-2.29 (m, 1H), 1.99-1.83 (m, 3H), 1.74-1.67 (m, 1H), 1.36-1.30 (m, 1H), 0.82 (s, 3H), 0.73 (s, 3H); <sup>13</sup>C NMR (100 MHz,

 $CDCl_3$ )  $\delta$  164.2, 136.4, 128.6, 128.3, 127.5, 55.9, 51.9, 49.0, 48.2, 44.1, 36.4, 30.9, 26.9, 19.5, 18.1; HRMS (ESI)  $C_{17}H_{23}N_2O_2S$  (M+H)<sup>+</sup> calcd. 319.1480, found 319.1490.

(S)-(+)- $N^{\alpha}$ -methyl cyclic camphor sulfonyl hydrazone (3b) Prepared according to the general procedure with methyl iodide to provide the title compound as a white solid in 92% yield; Mp 114-116 <sup>o</sup>C;  $[\alpha]^{20}_{D} = +84.7$  (c = 1.04, CHCl<sub>3</sub>); IR (neat) 2961, 1321, 1170 cm<sup>-1</sup>; 3b <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  3.26 (d, J = 13.6 Hz, 1H), 3.14 (d, J = 13.6 Hz, 1H), 3.13 (s, 3H), 2.59-2.53 (m, 1H), 2.41-2.35 (m, 1H), 2.08-2.04 (m, 2H), 2.00-1.93 (m, 1H), 1.83-1.76 (m, 1H), 1.45-1.39 (m, 1H), 1.01 (s, 3H), 0.93 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 164.2, 56.5, 49.4, 48.2, 44.5, 36.7, 35.0, 31.5, 27.3, 20.2, 18.3; HRMS (ESI)  $C_{11}H_{19}N_2O_2S$  (M+H)<sup>+</sup> calcd. 243.1167, found 243.1168.


(S)-(+)- $N^{\alpha}$ -ethyl cyclic camphor sulfonyl hydrazone (3c) Prepared according to the general procedure with ethyl bromide to provide the title compound as a white solid in 94% yield; Mp 91-93 <sup>o</sup>C;  $[\alpha]_{D}^{20} = +33.7$  (c = 1.145, CHCl<sub>3</sub>); IR (neat) 2974, 1324, 1171 3c cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  3.60-3.55 (m, 2H), 3.19 (d, J = 13.2 Hz, 1H), 3.12 (d, J = 13.2 Hz, 1H), 2.59-2.53 (m, 1H), 2.42-2.36 (m, 1H), 2.09-2.04 (m, 2H), 2.00-1.93 (m, 1H), 1.82-1.74 (m, 1H), 1.45-1.38 (m, 1H), 1.27 (t, J = 7.0 Hz, 3H), 0.99 (s, 3H), 0.92 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 163.7, 56.2, 49.3, 48.8, 44.5, 43.5, 36.7, 31.4, 27.3, 20.2, 18.3, 14.0; HRMS (ESI)  $C_{12}H_{21}N_2O_2S$  (M+H)<sup>+</sup> calcd. 257.1323, found 257.1319.



3d

(S)-(+)- $N^{\alpha}$ -n-butyl cyclic camphor sulfonyl hydrazone (3d) Prepared according to the general procedure with n-butyl bromide to provide the title compound as a white solid in 91% yield; Mp 66-67 °C;  $[\alpha]^{20}_{D} = +30.3$  (c = 1.055, CHCl<sub>3</sub>); IR (neat) 2948, 2872, 1325, 1161 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.55-3.40 (m, 2H), 3.19 (d, J = 13.2 Hz, 1H), 3.12 (d, J = 13.2 Hz, 1H), 2.58-2.52 (m, 1H), 2.41-2.34 (m, 1H), 2.08-2.03 (m, 2H), 2.00-1.91 (m, 1H), 1.81-1.74 (m, 1H), 1.71-1.63 (m, 2H), 1.44-1.29 (m, 3H), 0.99 (s, 3H), 0.92 (t, J = 7.4 Hz, 3H), 0.91 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  163.4, 56.2, 49.3, 48.7, 48.1, 44.5, 36.7, 31.4, 30.6, 27.3, 20.2, 20.1, 18.3, 14.0; HRMS (ESI) C<sub>14</sub>H<sub>25</sub>N<sub>2</sub>O<sub>2</sub>S (M+H)<sup>+</sup> calcd. 285.1636, found 285.1623.


(S)-(+)- $N^{\alpha}$ -n-Octyl cyclic camphor sulfonyl hydrazone (3e) Prepared according to the general procedure with *n*-octyl bromide to provide the title compound as a colorless oil in 91% yield;  $[\alpha]^{20}_{D} =$  3e +22.6 (c = 1.227, CHCl<sub>3</sub>); IR (neat) 2923, 2855, 1331, 1166 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  3.51-3.40 (m, 2H), 3.18 (d, *J* = 13.2 Hz, 1H), 3.12 (d, *J* = 13.2 Hz, 1H), 2.57-2.51 (m, 1H), 2.41-2.34 (m, 1H), 2.07-2.03 (m, 2H), 1.96-1.91 (m, 1H), 1.80-1.73 (m, 1H), 1.70-1.65 (m, 2H), 1.43-1.37 (m, 1H), 1.28-1.24 (m, 10H), 0.98 (s, 3H), 0.91 (s, 3H), 0.85 (t, J = 6.6 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ 163.4, 56.1, 49.3, 48.7, 48.3, 44.5, 36.7, 32.0, 31.4, 29.4, 28.5, 27.3, 26.8, 22.8, 20.1, 18.3, 14.3; HRMS (ESI) C<sub>18</sub>H<sub>33</sub>N<sub>2</sub>O<sub>2</sub>S (M+H)<sup>+</sup> calcd. 341.2262, found 341.2256.



(*S*)-(-)- $N^{\alpha}$ -9-methyl anthryl cyclic camphor sulfonyl hydrazone (3f) Prepared according to the general procedure with 9-chloromethyl anthracene to provide the title compound as a yellow solid in 82% yield; Mp 196-198 °C;  $[\alpha]^{20}_{D} = -45.0$  (c = 1.16, CHCl<sub>3</sub>); IR (neat) 2967, 1322, 1164 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.55 (d, *J* = 8.8 Hz, 2H),

8.44 (s, 1H), 7.98 (d, J = 8.4 Hz, 2H), 7.57-7.53 (m, 2H), 7.48-7.45 (m, 2H), 5.70 (d, J = 13.6 Hz, 1H), 5.47 (d, J = 14.0 Hz, 1H), 3.30 (d, J = 13.6 Hz, 1H), 3.24 (d, J = 13.6 Hz, 1H), 2.28-2.22 (m, 2H), 1.89-1.82 (m, 3H), 1.78-1.74 (m, 1H), 1.29-1.27 (m, 1H), 0.84 (s, 3H), 0.75 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  164.6, 131.8, 131.6, 129.0, 128.6, 127.0, 126.1, 125.2, 125.0, 56.0, 49.1, 48.8, 44.4, 43.0, 36.6, 31.6, 27.1, 20.0, 18.2; HRMS (MALDI-TOF) C<sub>25</sub>H<sub>26</sub>N<sub>2</sub>NaO<sub>2</sub>S (M+Na)<sup>+</sup> calcd. 441.1607, found 441.1594.

General procedure for preparation of  $N^{\alpha}$ -alkylated cyclic camphor sulfonyl hydrazines (5a-f) To a solution of 3a-f (1 mmol) in 2 ml methanol was added 2ml trifluoroacetic acid. The mixture was stirred at 0 °C and Sodium cyanoborohydride was added in portions. The reaction was then allowed to stir at room temperature. After consumption of the starting material (tracked by TLC), methanol was removed by evaporator. Water was added to the resulting mixture and use sodium hydroxide pellets to basify the solution to PH=9-10. Then the mixture was extracted with ethyl acetate for three times. The combined organic layer was washed with brine and dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>, followed by further purification via column chromatography to give compound **5a-f** in 25-96% yield.



(S)-(-)- $N^{\alpha}$ -Benzyl cyclic camphor sulfonyl hydrazine (5a) Prepared according to the general procedure with 3a to provide the title compound as a white solid in 80% yield; Mp 69-70 °C;  $[\alpha]^{20}_{D} = -87.4$  (c = 1.1, CHCl<sub>3</sub>); IR (neat) 3359, 2958, 2881,


1324, 1143 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.39-7.29 (m,

5H), 4.58 (d, J = 14.8 Hz, 1H), 4.06 (d, J = 14.8 Hz, 1H), 3.31 (d, J = 14.4 Hz, 1H), 3.22 (d, J = 14.4 Hz, 1H), 3.16 (dd, J = 8.8, 5.6 Hz, 1H), 1.76-1.51 (m, 5H), 1.32 (s, 3H), 1.23-1.17 (m, 1H), 1.13-1.07 (m, 1H), 0.94 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  136.0, 128.6, 128.4, 127.6, 62.5, 51.3, 50.7, 50.4, 46.7, 45.2, 37.2, 34.2, 25.9, 21.1, 20.6; HRMS (MALDI-TOF) C<sub>17</sub>H<sub>25</sub>N<sub>2</sub>O<sub>2</sub>S (M+H)<sup>+</sup> calcd. 321.1631, found 321.1628.

 $(S)-(-)-N^{\alpha}-Methyl cyclic camphor sulfonyl hydrazine (5b)$ Prepared according to the general procedure with 3b to provide the title compound as a white solid in 82% yield; Mp 81-83 °C;  $[\alpha]^{20}_{D} = -78.8$  (c **5b** = 1.05, CHCl<sub>3</sub>); IR (neat) 3294, 2961, 2880, 1334, 1145 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  3.31 (dd, J = 9.4, 5.8 Hz, 1H), 3.26 (d, J = 14.4 Hz, 1H), 3.16 (d, J = 14.8 Hz, 1H), 2.83 (s, 3H), 1.80-1.69 (m, 3H), 1.64-1.57 (m, 2H), 1.33 (s, 3H), 1.26-1.20 (m, 1H), 1.18-1.11 (m, 1H), 0.94 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  62.6, 51.6, 50.2, 46.9, 45.5, 37.4, 34.6, 34.4, 26.1, 21.4, 20.8; HRMS (ESI)

 $C_{11}H_{21}N_2O_2S (M+H)^+$  calcd. 245.1323, found 245.1320.


(S)-(-)- $N^{\alpha}$ -ethyl cyclic camphor sulfonyl hydrazine (5c) Prepared according to the general procedure with 3c to provide the title compound as a white solid in 81% yield; Mp 105 °C;  $[\alpha]^{20}_{D} = -111.3$ 5c (c = 1.05, CHCl<sub>3</sub>); IR (neat) 3359, 2956, 2878, 1333, 1176, 1143cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  4.00 (br, 1H), 3.42-3.34 (m, 1H), 3.23 (d, J = 14.4 Hz, 1H), 3.23-3.19 (m, 1H), 3.13 (d, J = 14.4 Hz, 1H), 3.05-2.96 (m, 1H), 1.78-1.68 (m, 3H), 1.65-1.56 (m, 2H), 1.33 (s, 3H), 1.24-1.10 (m, 2H), 1.19 (t, J = 7.0 Hz, 3H), 0.93 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  62.9, 51.3, 50.6, 46.5, 45.1, 41.4, 37.0, 34.1, 25.9, 21.1, 20.5, 12.3; HRMS (ESI) C<sub>12</sub>H<sub>23</sub>N<sub>2</sub>O<sub>2</sub>S (M+H)<sup>+</sup> calcd. 259.1480, found 259.1477; Anal. C<sub>12</sub>H<sub>22</sub>N<sub>2</sub>O<sub>2</sub>S calcd. C 55.78, H 8.58, N 10.84, S 12.41; found C 55.61, H 8.76, N 10.86, S 12.42.



(S)-(-)- $N^{\alpha}$ -ethyl cyclic camphor sulfonyl hydrazine (5d) Prepared according to the general procedure with 3d to provide the title compound as a colorless oil in 92% yield;  $[\alpha]^{20}_{D} = -88.4$ 

**5d** (c = 1.2, CHCl<sub>3</sub>); IR (neat) 2958, 2877, 1328, 1161, 1136 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.37-3.30 (m, 1H), 3.23 (d, J = 14.4 Hz, 1H), 3.21-3.18 (m, 1H), 3.12 (d, J = 14.0 Hz, 1H), 2.90-2.83 (m, 1H), 1.77-1.68 (m, 3H), 1.63-1.56 (m, 4H), 1.36-1.29 (m, 2H), 1.32 (s, 3H), 1.24-1.10 (m, 2H), 0.93 (s, 3H), 0.91 (t, J = 7.0 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 63.1, 51.5, 50.8, 46.9, 46.6, 45.5, 37.4, 34.5, 29.2, 26.2, 21.4, 20.8, 20.2, 14.0; HRMS (ESI) C<sub>14</sub>H<sub>27</sub>N<sub>2</sub>O<sub>2</sub>S (M+H)<sup>+</sup> calcd. 287.1793, found 287.1803.


(S)-(-)- $N^{\alpha}$ -ethyl cyclic camphor sulfonyl hydrazine (5e) Prepared according to the general procedure with 3e to provide the title compound as a colorless oil in 96% yield;  $[\alpha]^{20}_{D} = -76.8$  (c = 1.1, 5e CHCl<sub>3</sub>); IR (neat) 2922, 1733, 1733, 1455, 1328, 1136 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  3.33-3.28 (m, 1H), 3.23 (d, J = 14.4 Hz, 1H), 3.21-3.17 (m, 1H), 3.12 (d, J = 14.4 Hz, 1H), 2.88-2.83 (m, 1H), 1.77-1.68 (m, 3H), 1.61-1.56 (m, 4H), 1.39 (s, 3H), 1.27-1.10 (m, 12H), 0.93 (s, 3H), 0.87 (t, J = 12 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  63.1, 51.5, 50.8, 46.9, 45.5, 37.4, 34.5, 32.0, 29.4, 27.1, 27.0, 26.2, 22.9, 21.4, 20.8, 14.3; HRMS (ESI) C<sub>18</sub>H<sub>35</sub>N<sub>2</sub>O<sub>2</sub>S (M+H)<sup>+</sup> calcd. 343.2419, found 343.2425.




(*S*)-(+)- $N^{\alpha}$ -9-methyl anthryl cyclic camphor sulfonyl hydrazine (5f) Prepared according to the general procedure with 3f to provide the title compound as a yellow solid in 25% yield; Mp 151-153 °C;  $[\alpha]^{20}_{D} = +24.0$  (c = 0.9, CHCl<sub>3</sub>); IR (neat) 2956, 1322, 1140 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.48 (d, J = 9.6 Hz, 3H), 8.01 (d, J = 8.8 Hz, 2H),

7.57-7.46 (m, 4H), 5.58 (d, J = 14.0 Hz, 1H), 4.96 (d, J = 14.0 Hz, 1H), 4.15 (br, 1H), 3.36 (d, J = 14.4 Hz, 1H), 3.27 (d, J = 14.4, Hz, 1H), 2.74 (t, J = 7.4 Hz, 1H), 1.64-1.47 (m, 3H), 1.36 (s, 3H), 1.33 (m, 2H), 1.02-0.93 (m, 2H), 0.93 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  131.5, 131.3, 128.9, 128.3, 126.5, 126.0, 124.8, 124.7, 63.1, 51.3, 51.0, 46.6, 45.1, 41.8, 36.9, 34.1, 25.8, 21.1, 20.6; HRMS (MALDI-TOF) C<sub>25</sub>H<sub>28</sub>N<sub>2</sub>NaO<sub>2</sub>S (M+Na)<sup>+</sup> calcd. 443.17637, found 443.1764.

General procedure for Diels-Alder reaction Catalyst 5c (0.2 mmol, trichloroacetic acid (0.1 mmol) and  $\alpha,\beta$ -unsaturated aldehyde (1 mmol) was suspended in 1 ml brine. After stirring at room temperature for 5 minutes, the reaction was cooled down to 0 °C and a freshly distilled cyclopentadiene (6 mmol) was added. The reaction was kept at 0 °C until consumption of the starting material (tracked by TLC). 20 ml ethyl acetate and 5 ml water were added to the mixture. The separated organic layer was dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>, followed by further purification via column chromatography to give a mixture of Diels-Alder adduct.




(1*R*,2*S*,3*R*,4*S*)-3-Methylbicyclo[2,2,1]hept-5-ene-2-carboxaldehyde and (1*S*,2*S*,3*R*,4*R*)-3-Methylbicyclo[2,2,1]hept-5-ene-2-carboxaldehyde (Table 4, entry 1) Prepared according to the general procedure with *trans*-crotonaldehyde to provide the title compound as a colorless oil in 92% yield; 1:1.5 *exo:endo*, 83% *endo ee.* The *endo* enantiomeric excess was obtained by acetalization with (+)-(*R*,*R*)-hydrobenzoin and <sup>1</sup>H NMR analysis:<sup>1</sup> (400 MHz, C<sub>6</sub>D<sub>6</sub>) *endo* isomers  $\delta$ 5.07 (d, *J* = 8.4 Hz, CHO<sub>2</sub>, major isomer),  $\delta$  5.02 (d, *J* = 8.0 Hz, CHO<sub>2</sub>, miner isomer); IR (neat) 3445, 2959, 1699, 1455 cm<sup>-1</sup>; <sup>1</sup>H NMR, <sup>13</sup>C NMR data are in agreement with the published data.<sup>2,3</sup>




(1R,2S,3R,4S)-3-Propylbicyclo[2,2,1]hept-5-ene-2-carboxaldehyde and (1S,2S,3R,4R)-3-Propylbicyclo[2,2,1]hept-5-ene-2-carboxaldehyde (Table 4, entry 2) Prepared according to the general procedure with *trans*-2-hexenal to provide the title compound as a colorless oil in 71% yield; 1:1.3 exo:endo, 68% exo ee, 83% endo ee. The enantiomeric excess was determined by reduction of the formyl group (2.0 eq NaBH<sub>4</sub>,  $Et_2O/MeOH=2/1$  (v/v, 0.2 M)) followed by conversion of the resulting alcohol to the benzoyl ester (3.0 eq  $Et_3N$ , 0.1 eq DMAP and 1.1 eq BzCl,  $CH_2Cl_2$  (0.2 M)) and HPLC analysis. Enantiomers were separated by HPLC using a Daicel Chiralcel OD-H column guarded with Chiracel OD Guard column (n-Hexane / *i*-PrOH = 99.5 / 0.5; flow rate = 0.5 ml/min; *endo* isomers:  $T_R 1 = 24.7$  min (minor),  $T_R 2 = 26.1 \text{ min (major)}; exo \text{ isomers: } T_R 1 = 28.6 \text{ min (minor)}, T_R 2 = 30.2 \text{ min}$ (major)); The same *endo* enantiomeric excess was obtained by acetalization with (+)-(*R*,*R*)-hydrobenzoin and <sup>1</sup>H NMR analysis: (400 MHz,  $C_6D_6$ ) endo isomers  $\delta$  5.09 (d, J = 8.4 Hz, CHO<sub>2</sub>, major isomer),  $\delta$  5.03 (d, J = 8.0 Hz, CHO<sub>2</sub>, miner isomer); IR

(neat) 2960, 1704, 1466 cm<sup>-1</sup>; <sup>1</sup>H NMR, <sup>13</sup>C NMR data are in agreement with the published data.<sup>2,3</sup>




(1R,2R,3R,4S)-3-Phenylbicyclo[2,2,1]hept-5-ene-2-carboxaldehyde and (1S,2R,3R,4R)-3-Phenylbicyclo[2,2,1]hept-5-ene-2-carboxaldehyde (Table 4, entry 3) Prepared according to the general procedure with *trans*-cinnamaldehyde to provide the title compound as a colorless oil in 92% yield; 1:1.1 exo:endo, 78% exo ee, 93% endo ee. The enantiomeric excess was determined by reduction of the formyl group followed by conversion of the resulting alchol to the benzoyl ester and HPLC analysis. Enantiomers were separated by HPLC using a Daicel Chiralpak AD-H column guarded with Chiracel OD Guard column (*n*-Hexane / i-PrOH = 99 / 1; flow rate = 0.75 ml/min; endo isomers:  $T_R 1 = 13.8$  min (minor),  $T_R 2 = 20.0$  min (major); exo isomers:  $T_R 1 = 15.0$  min (minor),  $T_R 2 = 23.0$  min (major)); The same endo enantiomeric excess was obtained by acetalization with (+)-(R,R)-hydrobenzoin and <sup>1</sup>H NMR analysis: (400 MHz,  $C_6D_6$ ) endo isomers  $\delta$  5.22 (d, J = 8.0 Hz, CHO<sub>2</sub>, major isomer),  $\delta$  5.18 (d, J = 8.4 Hz, CHO<sub>2</sub>, miner isomer); IR (neat) 3061, 2972, 1716, 1601, 1496 cm<sup>-1</sup>; *exo* isomer <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  9.93 (d, J = 2.0 Hz, 1H), 7.34-7.15 (m, 5H), 6.35 (dd, J = 5.6, 3.2 Hz, 1H), 6.08 (dd, J = 5.6, 3.2 Hz, 1H), 3.74-3.72 (m, 1H), 3.24-3.22 (m, 2H), 2.62-2.59 (m, 1H), 1.65-1.61 (m, 1H), 1.58-1.55 (m, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 202.7, 142.5, 136.5, 136.2, 128.1, 127.8, 126.1, 59.4, 48.4, 47.5, 45.42, 45.35; endo isomer <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  9.61 (d, J = 2.0 Hz, 1H), 7.34-7.15 (m, 5H), 6.43 (dd, J = 5.6, 3.2 Hz, 1H), 6.18 (dd, J = 5.6, 2.8 Hz, 1H), 3.34 (s, 1H), 3.14-3.09 (m, 2H), 3.00-2.98 (m, 1H), 1.83-1.81 (m, 1H), 1.64-1.61 (m, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 203.5, 143.5, 139.2, 133.7, 128.5, 127.3, 126.3, 60.8, 48.3, 47.1, 45.6, 45.1.




# (1*R*,2*R*,3*R*,4*S*)-3-(4-Methoxyphenylbicyclo[2,2,1]hept-5-ene-2-carboxaldehyde and

(1S,2R,3R,4R)-3-(4-Methoxyphenylbicyclo[2,2,1]hept-5-ene-2-carboxaldehyde

(Table 4, entry 4) Prepared according to the general procedure with *trans*-cinnamaldehyde to provide the title compound as a colorless oil in 82% yield; 1:0.94 exo:endo, 81% exo ee, 91% endo ee. The enantiomeric excess was determined by reduction of the formyl group followed by conversion of the resulting alchol to the benzoyl ester and HPLC analysis. Enantiomers were separated by HPLC using a Daicel Chiralpak AD-H column guarded with Chiracel OD Guard column (n-Hexane / *i*-PrOH = 98 / 2; flow rate = 0.75 ml/min; *endo* isomers:  $T_R 1 = 16.5$  min (minor),  $T_R 2$ = 27.5 min (major); *exo* isomers:  $T_R 1 = 19.5$  min (minor),  $T_R 2 = 24.9$  min (major)); The same endo enantiomeric excess was obtained by acetalization with (+)-(*R*,*R*)-hydrobenzoin and <sup>1</sup>H NMR analysis: (400 MHz,  $C_6D_6$ ) endo isomers  $\delta$  5.25 (d, J = 8.0 Hz, CHO<sub>2</sub>, major isomer),  $\delta$  5.20 (d, J = 8.4 Hz, CHO<sub>2</sub>, miner isomer); IR (neat) 2963, 1716, 1611, 1513, 1248, 1035 cm<sup>-1</sup>; Mixture of *exo* and *endo* isomers <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  9.91 (d, J = 2.0 Hz, 1H), 9.58 (d, J = 2.0 Hz, 1H), 7.20-7.17 (m, 2H), 7.08-7.06 (m, 2H), 6.87-6.84 (m, 2H), 6.81-6.78 (m, 2H), 6.41 (dd, J = 5.8, 3.4 Hz, 1H), 6.34 (dd, J = 5.6, 3.2 Hz, 1H), 6.16 (dd, J = 5.8, 2.6 Hz, 1H), 6.07 (dd, J = 5.4, 3.0 Hz, 1H), 3.79 (s, 3H), 3.77 (s, 3H), 3.66 (dd, J = 5.2, 3.6 Hz, 1H), 3.32 (s, 1H), 3.21 (d, J = 1.6 Hz, 1H), 3.17 (s, 1H), 3.07 (d, J = 1.2 Hz, 1H), 3.03 (d, J = 5.2 Hz, 1H), 2.95-2.92 (m, 1H), 2.55-2.53 (m, 1H), 1.79 (d, J = 8.8 Hz, 1H),1.62-1.59 (m, 2H), 1.56-1.53 (m, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 203.7, 202.9, 157.9, 157.8, 139.0, 136.3, 136.1, 135.4, 134.4, 133.5, 128.6, 128.1, 113.8, 113.3, 60.7, 59.4, 55.1, 55.0, 48.5, 48.4, 47.4, 46.9, 45.3, 44.91, 44.86, 44.5; HRMS (ESI)  $C_{15}H_{17}O_2 (M+H)^+$  calcd. 229.1228, found 229.1222.




(1R,2R,3R,4S)-3-(4-Nitrophenylbicyclo[2,2,1]hept-5-ene-2-carboxaldehyde and (1S,2R,3R,4R)-3-(4-Nitrophenylbicyclo[2,2,1]hept-5-ene-2-carboxaldehyde (Table 4, entry 5) Prepared according to the general procedure with *trans*-cinnamaldehyde to provide the title compound as a colorless oil in 99% yield; 1:1.1 exo:endo, 81% exo ee, 91% endo ee. The enantiomeric excess was determined by reduction of the formyl group followed by conversion of the resulting alchol to the benzoyl ester and HPLC analysis. Enantiomers were separated by HPLC using a Daicel Chiralpak AD-H column (n-Hexane / i-PrOH = 96 / 4; flow rate = 1 ml/min; endo isomers:  $T_R 1 = 16.2 \text{ min (minor)}, T_R 2 = 28.4 \text{ min (major)}; exo isomers: <math>T_R 1 = 16.2 \text{ min (minor)}, T_R 2 = 28.4 \text{ min (major)}; exo isomers: T_R 1 = 16.2 \text{ min (minor)}, T_R 2 = 28.4 \text{ min (major)}; exo isomers: T_R 1 = 16.2 \text{ min (minor)}, T_R 2 = 28.4 \text{ min (major)}; exo isomers: T_R 1 = 16.2 \text{ min (minor)}, T_R 2 = 28.4 \text{ min (major)}; exo isomers: T_R 1 = 16.2 \text{ min (minor)}, T_R 2 = 28.4 \text{ min (major)}; exo isomers: T_R 1 = 16.2 \text{ min (minor)}; exo isomers:$ 15.0 min (minor),  $T_R 2 = 19.5$  min (major)); The same *endo* enantiomeric excess was obtained by acetalization with (+)-(R,R)-hydrobenzoin and <sup>1</sup>H NMR analysis: (400 MHz, C<sub>6</sub>D<sub>6</sub>) endo isomers  $\delta$  5.11 (d, J = 8.4 Hz, CHO<sub>2</sub>, major isomer),  $\delta$  5.04 (d, J = 8.0 Hz, CHO<sub>2</sub>, miner isomer); IR (neat) 3063, 2973, 1716, 1598, 1520, 1344, cm<sup>-1</sup>; <sup>1</sup>H NMR, <sup>13</sup>C NMR data are in agreement with the published data.<sup>1</sup>




(1*R*,2*R*,3*R*,4*S*)-3-(2-Nitrophenylbicyclo[2,2,1]hept-5-ene-2-carboxaldehyde and (1*S*,2*R*,3*R*,4*R*)-3-(2-Nitrophenylbicyclo[2,2,1]hept-5-ene-2-carboxaldehyde (Table 4, entry 6) Prepared according to the general procedure with *trans*-crotonaldehyde to provide the title compound as a colorless oil in 94% yield; 1:2.5 *exo:endo*, 72% *exo ee*, 90% *endo ee*. The *endo* enantiomeric excess was obtained by acetalization with

(+)-(*R*,*R*)-hydrobenzoin and <sup>1</sup>H NMR analysis:<sup>1</sup> (400 MHz, C<sub>6</sub>D<sub>6</sub>) *exo* isomers  $\delta$  5.44 (d, *J* = 4.4 Hz, CHO<sub>2</sub>, major isomer),  $\delta$  5.36 (d, *J* = 5.2 Hz, CHO<sub>2</sub>, miner isomer) *endo* isomers  $\delta$  5.06 (d, *J* = 7.6 Hz, CHO<sub>2</sub>, major isomer),  $\delta$  4.97 (d, *J* = 7.6 Hz, CHO<sub>2</sub>, miner isomer); IR (neat) 3065, 2978, 1714, 1519, 1354 cm<sup>-1</sup>; <sup>1</sup>H NMR, <sup>13</sup>C NMR data are in agreement with the published data.<sup>1</sup>



(1*R*,2*R*,3*R*,4*S*)-3-(4-Chlorophenylbicyclo[2,2,1]hept-5-ene-2-carboxaldehyde and (1*S*,2*R*,3*R*,4*R*)-3-(4-Chlorophenylbicyclo[2,2,1]hept-5-ene-2-carboxaldehyde

(Table 4, entry 7) Prepared according to the general procedure with *trans*-cinnamaldehyde to provide the title compound as a colorless oil in 81% yield; 1:1.1 *exo:endo*, 84% *exo ee*, 96% *endo ee*. The enantiomeric excess was determined by reduction of the formyl group followed by conversion of the resulting alchol to the benzoyl ester and HPLC analysis. Enantiomers were separated by HPLC using a Daicel Chiralcel OD-H column (*n*-Hexane / *i*-PrOH = 98 / 2; flow rate = 0.5 ml/min; *endo* isomers:  $T_R 1 = 7.5$  min (minor),  $T_R 2 = 14.0$  min (major); *exo* isomers:  $T_R 1 = 8.3$  min (minor),  $T_R 2 = 21.9$  min (major)); The same *endo* enantiomeric excess was obtained by acetalization with (+)-(*R*,*R*)-hydrobenzoin and <sup>1</sup>H NMR analysis: (400 MHz, C<sub>6</sub>D<sub>6</sub>) *endo* isomers  $\delta$  5.25 (d, *J* = 8.0 Hz, CHO<sub>2</sub>, major isomer),  $\delta$  5.20 (d, *J* = 8.4 Hz, CHO<sub>2</sub>, miner isomer); IR (neat) 3064, 2973, 1716, 1493, 727 cm<sup>-1</sup>; <sup>1</sup>H NMR, <sup>13</sup>C NMR data are in agreement with the published data.<sup>1</sup>



(1*R*,2*R*,3*R*,4*S*)-3-(4-Bromophenylbicyclo[2,2,1]hept-5-ene-2-carboxaldehyde and (1*S*,2*R*,3*R*,4*R*)-3-(4-Bromophenylbicyclo[2,2,1]hept-5-ene-2-carboxaldehyde

(Table 4, entry 7) Prepared according to the general procedure with *trans*-cinnamaldehyde to provide the title compound as a colorless oil in 81% yield; 1:1.1 *exo:endo*, 86% *exo ee*, 96% *endo ee*. The enantiomeric excess was determined by reduction of the formyl group followed by conversion of the resulting alchol to the benzoyl ester and HPLC analysis. Enantiomers were separated by HPLC using a Daicel Chiralcel OD column (gradient, 0-10min, *n*-Hexane / *i*-PrOH = 98 / 2, 15min, *n*-Hexane / *i*-PrOH = 85 / 15; flow rate = 0.8 ml/min; *endo* isomers: T<sub>R</sub>1 = 8.6 min (minor), T<sub>R</sub>2 = 19.5 min (major); *exo* isomers: T<sub>R</sub>1 = 9.9 min (minor), T<sub>R</sub>2 = 24.0 min (major)); The same *endo* enantiomeric excess was obtained by acetalization with (+)-(*R*,*R*)-hydrobenzoin and <sup>1</sup>H NMR analysis: (400 MHz, C<sub>6</sub>D<sub>6</sub>) *endo* isomers  $\delta$  5.25 (d, *J* = 8.0 Hz, CHO<sub>2</sub>, major isomer),  $\delta$  5.20 (d, *J* = 8.4 Hz, CHO<sub>2</sub>, miner isomer); IR (neat) 3063, 2971, 1714, 1489, 517 cm<sup>-1</sup>; <sup>1</sup>H NMR, <sup>13</sup>C NMR data are in agreement with the published data.<sup>4</sup>

## Reference

(1) Lemay, M.; Ogilvie, W. W. Org. Lett. 2005, 7, 4141.

(2) Ishihara, K.; Kurihara, H.; Matsumoto, M.; Yamamoto, H. J. Am. Chem. Soc. **1998**, *120*, 6920.

(3) Ahrendt, K. A.; Borths, C. J.; MacMillan, D. W. C. J. Am. Chem. Soc. 2000, 122, 4243.

(4) Gotoh, H.; Hayashi, Y. Org. Lett. 2007, 9, 2859.

